0001104659-16-151946.txt : 20161025 0001104659-16-151946.hdr.sgml : 20161025 20161025163346 ACCESSION NUMBER: 0001104659-16-151946 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161025 FILED AS OF DATE: 20161025 DATE AS OF CHANGE: 20161025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vitae Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001157602 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043567753 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 502 WEST OFFICE CENTER DR CITY: FORT WASHINGTON STATE: PA ZIP: 19034 BUSINESS PHONE: 215-461-2000 MAIL ADDRESS: STREET 1: 502 WEST OFFICE CENTER DR CITY: FORT WASHINGTON STATE: PA ZIP: 19034 FORMER COMPANY: FORMER CONFORMED NAME: Vitae Pharmaceuticals Inc DATE OF NAME CHANGE: 20050118 FORMER COMPANY: FORMER CONFORMED NAME: CONCURRENT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sable Carole CENTRAL INDEX KEY: 0001604066 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36617 FILM NUMBER: 161950735 MAIL ADDRESS: STREET 1: C/O SCYNEXIS, INC. STREET 2: 3501 C TRICENTER BOULEVARD CITY: DURHAM STATE: NC ZIP: 27713 4 1 a4.xml 4 X0306 4 2016-10-25 1 0001157602 Vitae Pharmaceuticals, Inc VTAE 0001604066 Sable Carole C/O VITAE PHARMACEUTICALS, INC. 502 WEST OFFICE CENTER DR. FORT WASHINGTON PA 19034 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 10.51 2016-10-25 4 D 0 150000 10.49 D 2026-06-05 Common Stock 150000 0 D Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. This option, which provided for vesting with respect to 1/4 of the shares of stock which are subject to this option June 6, 2017 (the "Initial Vesting Date") and 1/48th of the shares of stock which are subject to this option monthly following the Initial Vesting Date, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. /s/ Carole Sable 2016-10-25